Company News – Ymmunobio

Ymmunobio Collaborates with Solid IO

Ymmunobio — Wed, 21 Oct 2026 20:47:03 +0000

We are pleased to announce a new collaboration with Solid IO 📣.

As we advance our oncology pipeline, understanding how our antibody-based cancer therapies perform in human tumor tissue is an important step. Working with Solid IO allows us to generate functional data directly in human tumor samples, complementing the preclinical data we have gathered so far.

“Understanding how our therapies perform in human tumor tissue is highly valuable as we advance our oncology pipeline. Through this collaboration with Solid IO, we aim to gain functional insights that complement our existing preclinical data and help guide our development decisions.”

~ Peter Schiemann, CEO, Ymmunobio

We thank the Solid IO team for their support and look forward to working together on the next steps in developing new cancer therapies.

Read more about the collaboration on the Solid IO blog.

Ymmunobio Publishes Preclinical Data on YB-800 in Cancer Cell International

Ymmunobio — Thu, 08 Oct 2026 22:27:44 +0000

Exciting news from Ymmunobio and our collaborators at the University Clinic Essen, Germany: we’ve published new work establishing NPTXR as a novel tumor‑associated antigen and demonstrating the therapeutic potential of YB‑800–based antibody–drug conjugates (ADCs) in preclinical tumor models.
In this Cancer Cell International study, we show that YB‑800, a first‑in‑class humanized monoclonal antibody against NPTXR, binds selectively to tumor cells, undergoes efficient internalization, and enables potent, tumor‑targeted ADC activity in gastrointestinal and other solid tumor indications where NPTXR is overexpressed.

This work further validates NPTXR as a promising target for next‑generation ADCs and underpins our ongoing efforts to translate this biology into clinical candidates.

🔗 Read the full paper: https://rdcu.be/fyxqE

Ymmunobio Achieves Major Preclinical Milestone with YB-800 ADCs

Ymmunobio — Sat, 19 Apr 2025 09:58:39 +0000

RIEHEN, Switzerland, April 18, 2025 /PRNewswire/ — Ymmunobio AG (YB), a Swiss-based global biotech company dedicated to the development of new cancer therapeutics, is proud to announce that its two-antibody drug conjugate (ADC) assets, YB-800ADC1 and YB-800ADC2, have completed the preclinical proof of concept studies. Both in vivo and in vitro studies have reached this important milestone by demonstrating the anti-tumor efficacy of both ADCs.

Read the full report here.

Ymmunobio & Paul-Scherrer Institute win Innosuisse grant to develop radiopharmaceutical with YB-800

Ymmunobio — Sun, 26 Jan 2025 14:06:14 +0000

We are excited to report that our collaboration with the PSI, supported by an Innosuisse Grant, is kicking off now! Sonne there will be the first results to be reported about our radio pharmaceutical project.

Check out the full report here: https://lnkd.in/eZWU49gD

We are very proud to announce our 3rd place achievement at the Prix Galien USA Awards!

Ymmunobio — Thu, 14 Nov 2024 14:27:42 +0000

We are honored to be nominated and thrilled to secure 3rd place at this presigious event! Although typically only the winner is announced, a Prix Galien Foundation team member remembered Ymmunobio because of our unique name and that “Y” in front – it sparked a conversation and a smile!

Read the full article here: https://www.linkedin.com/feed/update/urn:li:activity:7262811531346685953

A big thank you to everyone who helped make this night memorable, and here’s to many more innovative milestones ahead!

Countdown to the Prix Galien Awards: Showcasing Science-Driven Innovation in NYC!

Ymmunobio — Wed, 30 Oct 2024 17:01:00 +0000

In just two weeks Ymmunobio is heading to New York for the prestigious Prix Galien USA Awards, where we’ll be competing in the “Best Startup” category!

It’s an incredible honor to be recognized by such an esteemed foundation that celebrates innovation and excellence in life sciences and healthcare.

Read the full post on LinkedIn →

Ymmunobio and EVIIVE announce collaboration to develop advanced liquid biopsy for detecting NPTXR in cancer patients

Ymmunobio — Fri, 21 Jun 2024 22:05:30 +0000

We are thrilled to announce a groundbreaking partnership between Ymmunobio and EVIIVE to advance the future of cancer diagnostics!

Together, we are developing an innovative liquid biopsy technology using extracellular vesicles (EVs), enhancing precision in disease detection and monitoring. Our joint efforts will leverage Ymmunobio’s cutting-edge biotechnological expertise and EVIIVE’s advanced diagnostic platforms to create a revolutionary tool in the fight against cancer.

Ymmunobio and EVIIVE are pioneering advances in diagnostics and oncology, working towards a future where healthcare is more personalized, precise, and effective for all patients.

Stay tuned for more updates as we work towards a brighter, healthier future!

Read the full press release here:

https://www.einpresswire.com/article/719981774/ymmunobio-and-eviive-announce-collaboration-to-develop-advanced-liquid-biopsy-for-detecting-nptxr-in-cancer-patients

Ymmunobio is proud to announce our ASCO publication on YB-800

Ymmunobio — Mon, 03 Jun 2024 22:07:00 +0000

We are thrilled to announce that Ymmunobio’s abstract has been published in the American Society of Clinical Oncology (ASCO) annual conference publications:

“YB-800, a monoclonal antibody targeting the human neuronal pentraxin receptor (NPTXR), as a potential candidate for the design of a first-in-class antibody-drug conjugate (ADC) as a novel therapeutic intervention in gastro-intestinal cancers”

The full publication can be found here.

The abstract highlights using a fully humanized monoclonal antibody, YB-800, directed against the human neuronal pentraxin receptor (NPTXR). The expression of NPTXR has been associated with disease progression in several GI Cancers, including gastric, esophageal, colorectal, pancreatic, bladder and liver as well as breast and thyroid cancer. These findings provided a strong rationale for the design of a YB-800 based ADC, offering a novel therapeutic intervention option for patients with high unmet medical needs.

We are thrilled to contribute to the advancement of cancer treatment and dedicated to pursuing innovative therapies that can significantly impact patient care.

Global Business Report interviews Ymmunobio CEO Peter Schiemann

Ymmunobio — Sat, 11 May 2024 22:22:00 +0000

Check out the latest GBR Connect Series interview with our CEO and Co-Founder
Peter Schiemann, where he talks about the latest Ymmunobio Developments and the key focus areas for 2024 to establish a positive proof of concept with our ADC candidate YB800 targeting a new receptor in GI Cancers.

You can access the full interview here: Global Business Reports – Peter Schiemann (gbreports.com )

Ymmunobio has been selected for the Venture Leaders Biotech 2024!

Ymmunobio — Sat, 11 May 2024 22:09:00 +0000

We are very proud to announce that Ymmunobio is one of 10 Start-ups that has been selected for the Venture Leaders Biotech 2024.

Selected from over 70 applicants by a jury of investors and biotech experts, Ymmunobio will join the roadshow in Boston, one of the world’s most important life science hubs.
From May 13th – 17th 2024, the roadshow will connect the participants with international investors and industry leaders, accelerating their ventures’ expansion the US.

Go to the Venture Leaders Biotech Website for more information.